Stuckey: Vical Has A Deep Bench And Near Term Catalysts In my previous Biotechnology industry article, A Journey To Add Biotech To The Portfolio , I investigated the Biotechnology industry to find some companies that might be worth investing in
By Quoth the Raven: There is a war on between bulls and bears for the fate of biotech startup Amarin ( AMRN ). The next piece of the puzzle will fill itself in on Sunday this weekend, and it's going to be extremely
By Tech Guru : With a potential U.S. market for Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) patients of almost $1bb, based on 5mm CKD patients above age 65, of whom ~50% are in stage 3-5, there is ample opportunity for a few under-appreciated stories focusing on this market to
ever since the company reported successful Phase III results. Despite the incredible strength of the broader market and the biotech sector in particular this year, AMRN is down 14% YTD as of the time of writing. Since the company released Q1 2013 financial
AMGN ) incorporated in 1980 is a global biotechnology company that discovers, develops, manufactures ..... Headquartered in Thousand Oaks California, the biotech major employs approximately 18,000 ..... care, nephrology and inflammation. The biotech major is led by Robert A. Bradway who
By Chris Lacoursiere : The annual conference of The American Society of Clinical Oncology (ASCO) is currently less than a few days away, and what is the buzz for this year's conference? Immunotherapy is the buzz word for this year's conference. Bavituximab is a phosphatidylserine (PS) binding ...
Ultra rare diseases have become big business for both pharmaceutical and biotechnology companies, such as Alexion ( ALXN ). The specialty drug market is growing faster than the non-orphan drug market. Last year
May 23 (Reuters) - Forest Laboratories Inc said on Thursday that Howard Solomon, who has led the biotech firm since 1977, will retire as chief executive officer at the end of this year and the...
By Zacks Investment Research : After a big earnings beat two weeks ago, biotech company Santarus Inc ( SNTS ) became a Zacks #1 Rank Strong Buy on May 7. Since then, shares have climbed over 5%. Santarus
NEW YORK, May 22 (Reuters) - Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals.